Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.34 |
| ▸ | FEN1 | P39748 | 6/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108632 | 0.85 | RXFP1 (0.39) | KCNA5FNTAFNTBALOX5APFEN1 | |
| SCHEMBL6166428 | 0.84 | CNR1 (0.36) | FNTAFNTBPTGS1PTGS2TBXA2R | |
| SCHEMBL7105798 | 0.78 | POLB (0.37) | FNTAFNTBGPR119P2RY12 | |
| SCHEMBL6468248 | 0.72 | F10 (0.43) | KCNA5ALOX5APFEN1 | |
| SCHEMBL6163789 | 0.69 | ALOX5 (0.38) | ALOX5APFEN1GPR119 | |
| SCHEMBL6163480 | 0.69 | POLB (0.44) | FNTAFNTBPTGS1PTGS2 | |
| SCHEMBL7107442 | 0.68 | AGTR2 (0.37) | TBXA2RP2RY12 | |
| SCHEMBL7105111 | 0.67 | F2RL3 (0.45) | FNTAFNTB | |
| SCHEMBL6165250 | 0.67 | FNTA (0.51) | FNTAFNTB | |
| SCHEMBL7103244 | 0.67 | CYP19A1 (0.44) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | KCNA5 3170/4885FNTA 654/4885FNTB 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.